Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.67 |
| ▸ | TP53 | P04637 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12980301 | 0.87 | MAPT (0.76) | MAPTTP53SMN1; SMN2RXFP1LMNA | |
| SCHEMBL13173989 | 0.86 | MAPT (0.76) | MAPTTP53SMN1; SMN2RXFP1LMNA | |
| SCHEMBL13173972 | 0.84 | MAPT (0.78) | MAPTTP53SMN1; SMN2RXFP1LMNA | |
| SCHEMBL12963192 | 0.83 | TP53 (0.69) | MAPTTP53SMN1; SMN2RXFP1LMNA | |
| SCHEMBL24711450 | 0.82 | MAPT (0.69) | MAPTTP53SMN1; SMN2RXFP1LMNA | |
| SCHEMBL12980459 | 0.81 | MAPT (0.75) | MAPTTP53SMN1; SMN2RXFP1LMNA | |
| SCHEMBL12935589 | 0.79 | MEN1 (0.76) | MAPTTP53SMN1; SMN2RXFP1LMNA | |
| SCHEMBL25208976 | 0.79 | MAPT (0.68) | MAPTTP53SMN1; SMN2RXFP1LMNA | |
| SCHEMBL30446589 | 0.79 | MAPT (0.68) | MAPTTP53SMN1; SMN2RXFP1LMNA | |
| SCHEMBL24710841 | 0.79 | MAPT (0.72) | MAPTTP53SMN1; SMN2RXFP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8993604-B2 | Treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993604-B2 | Treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-8993604-B2 | Treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-10-11 | — | — | US | disclosed |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-10-11 | — | — | US | disclosed |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-10-11 | — | — | US | disclosed |
| WO-2011002635-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2011-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | HAVCR2, TTPA, CHIA | MAPT 118/4885TP53 2739/4885SMN1; SMN2 814/4885 |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | HAVCR2, TTPA, CHIA | MAPT 118/4885TP53 2739/4885SMN1; SMN2 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.